Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Next Previous
Trial Profile

Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalpiciclib (Primary) ; Exemestane (Primary) ; Goserelin (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin
  • Indications HER2 negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 12 Jul 2024 New trial record
  • 04 Jun 2024 Results investigating the efficacy of dalpiciclib, exemestane and goserelin as neoadjuvant therapy in premenopausal women with HR-positive, HER2-negative breast cancer were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top